相关实验视频

Updated: Jul 16, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

通过免疫原型化和药物向来增强个性化的免疫检查点疗法

Claudia Cerella¹, Mario Dicato¹, Marc Diederich²

¹Laboratoire de Biologie Moléculaire et Cellulaire du Cancer (LBMCC), Fondation Recherche sur le Cancer et les Maladies du Sang, Pavillon 2, 6A rue Barblé, L-1210 Luxembourg, Luxembourg.

Pharmacological research

|September 15, 2023

概括

免疫检查点抑制剂 (ICI) 的预测标记对于癌症治疗至关重要. 本综述探讨了基于瘤免疫原型和T细胞多样性的新型标记物,以改善患者分层和个性化免疫疗法.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
计算生物学计算生物学

背景情况:

免疫检查点抑制剂 (ICI) 在癌症治疗中表现有前途,但往往面临阻力.
缺乏预测标志物限制了患者分层和个性化治疗策略.
瘤微环境 (TME) 的特征,包括免疫细胞的组成和分布,是治疗反应的关键.

研究的目的:

审查当前的ICI格局,并探索新的预测标记.
讨论TME免疫原型,以进行个性化免疫分析和患者分层.
检查T细胞多样性和TME内的时空相互作用,以预测ICI疗效.

主要方法:

对ICI和预测生物标志物的当前文献的审查.
对TME免疫原型进行患者分层分析.
在TME中探索T细胞多样性和时空调节.
小分子作为潜在的ICI或TME调节器的概述.

主要成果:

TME免疫原型为个性化免疫分析提供了一个框架.
了解T细胞多样性及其在TME内的相互作用对于ICI反应至关重要.
在in silico中识别的化合物显示出潜在的ICI治疗的验证药物候选者.

结论:

基于TME组成和T细胞动态的新型预测标记可以增强ICI治疗的患者分层.
个性化免疫疗法可以通过整合免疫原型和T细胞分析来改进.
小分子为开发新的ICI或调节TME提供了一个有希望的途径.

关键词:

癌症免疫力癌症免疫力细胞异质性细胞异质性免疫检查站免疫检查站预测性标记是指预测性的标记.这些T细胞是T细胞.瘤微环境是一个微环境.

更多相关视频

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cell-mediated Immune Responses

Cell-mediated Immune Responses